Literature DB >> 24216525

Coronary artery bypass graft surgery remains the standard of care for patients with diabetes.

Emmanuel Moss1, Mahboob Alam, Christie M Ballantyne, John D Puskas.   

Abstract

Coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) are proven effective treatments of coronary artery disease (CAD), however, the optimal revascularization strategy remains unclear in certain patient subsets. The recently published "Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)" trial is a randomized study evaluating the use of CABG vs PCI in diabetic patients with multivessel coronary disease. The purpose of this editorial is to review the FREEDOM trial and the available literature guiding clinicians to make evidence-based decisions when treating diabetic patients with multivessel coronary disease. The current evidence suggests that CABG should remain the standard of care for this patient population.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Keywords:  CABG; Coronary artery disease; Diabetes; PCI

Mesh:

Year:  2013        PMID: 24216525     DOI: 10.1053/j.semtcvs.2013.07.007

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  2 in total

1.  Recovery of Left Ventricular Function After Percutaneous Coronary Intervention Compared to Coronary Artery Bypass Grafting in Patients with Multi-Vessel Coronary Disease and Left Ventricular Dysfunction.

Authors:  Noa P Yee; Andrea M Siu; James Davis; John Kao
Journal:  Hawaii J Med Public Health       Date:  2016-09

2.  Comparing clinical outcomes in patients with diabetes undergoing coronary artery bypass graft and percutaneous coronary intervention in real world practice in Iranian population.

Authors:  Arezo Arabi; Behshad Naghshtabrizi; Hamid Reza Baradaran; Yousef Moradi; Mohsen Asadi-Lari; Ali Mehrakizadeh
Journal:  BMC Cardiovasc Disord       Date:  2022-03-03       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.